2017.03.23|Lisbeth Heilesen The RedHill team assembled in Denmark. From left to right: Terry F. Plasse (MD, Medical Director, ReHill Biopharma), Danielle T. Abramson (Ph.D., Director, Intellectual Property and Research, RedHill Biopharma), Mark L. Levitt, (MD, Ph.D., Medical Director, Oncology, RedHill Biopharma), Emil Oldenburg (M.Sc., Scientific Assistant, Aarhus University), Christine R. Schar (Ph.D., Postdoctoral Fellow, Aarhus University) and Jan K. Jensen (Ph.D., Project Manager, Aarhus University). [Translate to English:] Den Israelske Biotek virksomhed RedHill Biopharma Ltd (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) har forlænget sit samarbejde med forskere ved Aarhus Universitet...
|